CagriSema weight loss women research: 7 Important Findings From REDEFINE 1 (2026)

Novo Nordisk reported that women assigned to investigational CagriSema in a post-hoc analysis of its REDEFINE 1 trial had an estimated average 25.0% weight reduction after 68 weeks, versus 3.0% with placebo, under an efficacy estimand assuming continued treatment without additional weight-loss therapies. The analysis included 2,309 women and was presented at The Menopause Society 2026 Annual Meeting, according to Novo Nordisk’s October 20, 2026 announcement—not at EASD 2025. These are company-reported, exploratory subgroup findings, not a new randomized trial designed specifically to compare women with men. [1]

Table of contents

1. What was actually studied?
2. Seven findings worth understanding
3. CagriSema weight loss women research: the numbers
4. Why estimands and post-hoc design matter
5. Menopause, hormones and scientific uncertainty
6. Safety signals and study boundaries
7. What researchers should investigate next
8. Frequently asked questions
9. References

What was actually studied?

The foundational REDEFINE 1 study was a phase 3, 68-week, double-blind, randomized trial among adults with obesity, or overweight with a related condition, who did not have type 2 diabetes. Its results were published by Garvey and colleagues in the New England Journal of Medicine in 2025. The trial randomized 3,417 participants across combination therapy, semaglutide alone, cagrilintide alone and placebo. [2]

CagriSema combines two investigationally evaluated pathways: semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and cagrilintide, a long-acting amylin analogue. They engage different biological mechanisms involved in appetite and energy intake. Describing the mechanisms does not establish that every person will respond similarly or that all observed effects arise from one pathway.

The main trial had a prespecified research design and enrolled both sexes. Later, investigators looked back at data from women. That is the defining distinction in CagriSema weight loss women research: investigators did not create a new women-only randomized study. They analyzed a subset of participants from the existing trial, generating useful questions that warrant prospective testing.

Novo Nordisk’s October 2026 announcement describes two separate post-hoc reports. The first evaluated 2,309 women across four randomized treatment arms. The second examined 1,902 women in the combination and placebo arms and categorized them by estimated menopausal stage. The two denominators refer to different analyses; treating them as interchangeable would obscure the methods. [1]

The women’s findings were presented as conference posters, P-51 and P-50, at The Menopause Society 2026 Annual Meeting. Their status differs from the peer-reviewed 2025 publication covering REDEFINE 1 overall. A corporate release can report authentic trial-derived findings while still providing less independent scrutiny and less methodological detail than a full peer-reviewed subgroup paper. That disclosure belongs in every summary of CagriSema weight loss women research.

Seven findings worth understanding

1. The women-only average was substantial, but conditional

The headline in CagriSema weight loss women research is the company-reported 25.0% estimated mean weight reduction with the combination at week 68, compared with 3.0% for placebo. These are group averages estimated under an efficacy framework; they are not a promise of individual results, nor the percentage of participants who lost that exact amount. [1]

The distinction between an average and an individual trajectory matters. Participants have different baselines, experiences, adherence patterns and biological contexts. A group mean condenses this variation into one statistical summary. Without the full distribution and subgroup modeling, the average cannot explain who benefited most, who discontinued or how consistently outcomes persisted. This is a central limitation of CagriSema weight loss women research.

When describing CagriSema weight loss women research, a responsible headline therefore includes the duration, the trial population, the analysis type and the estimand. Removing any one of these can make the figure look more general than the evidence supports.

2. The comparison included two individual components

Novo Nordisk reported, for the women’s efficacy-estimand analysis, estimated mean weight changes of 25.0% with CagriSema, 19.0% with semaglutide alone, 13.4% with cagrilintide alone and 3.0% with placebo. These values describe women in the respective randomized arms, not a head-to-head trial exclusively designed around sex differences. [1]

The individual components are scientifically important because the combination could be interpreted against each constituent. It would nevertheless be premature to infer synergy or a special female-specific interaction solely from the size of the differences. Establishing interactions requires suitable prespecified statistical models, sufficient power and appropriate adjustment for multiple comparisons. CagriSema weight loss women research does not replace those tests.

CagriSema weight loss women research invites comparisons but also requires disciplined attribution. A larger numerical outcome in one arm does not by itself isolate why the difference arose, whether it is stable across populations, or whether a specific physiological mechanism explains it.

3. Waist circumference changed alongside body weight

In the same women-only analysis, Novo Nordisk reported estimated mean waist-circumference changes of −20.5 cm with combination therapy, −17.4 cm with semaglutide alone, −11.7 cm with cagrilintide alone and −4.7 cm with placebo under the efficacy estimand. [1] Waist circumference offers a complementary anthropometric measure, although it is not a direct imaging measurement of visceral fat.

This detail helps interpret CagriSema weight loss women research beyond one number on a scale. Abdominal dimensions can change with total body mass, fat distribution and other factors. A smaller waist may be relevant to metabolic research, but it does not prove a specific change in organ fat, disease incidence or long-term cardiovascular events.

For future work, researchers could pair circumference measures with rigorously collected imaging, metabolic markers and functional outcomes. Such studies could clarify whether weight reduction and changes in regional adiposity track together in different reproductive stages. This would extend CagriSema weight loss women research beyond waist measurements.

4. Threshold outcomes provide a second view

The company-reported women-only analysis estimated that 93.3% of the CagriSema group achieved at least 10% weight reduction and 68.7% achieved at least 20% under the efficacy estimand. The respective placebo estimates were 12.7% and 1.8%. [1] These threshold proportions answer a different question from the average: how many participants crossed defined cutoffs in the model?

This part of CagriSema weight loss women research is potentially informative because a mean can conceal unequal response patterns. Still, threshold estimates are not equivalent to real-world persistence, and the company release does not supply every distributional detail readers might want. Reporting both means and thresholds gives a fuller, though incomplete, picture.

Threshold analyses also illustrate a general research principle: the selection of an endpoint shapes the story. Different endpoints may be meaningful for different scientific questions. The finding should be read alongside safety, durability, quality-of-life and maintenance evidence rather than as a stand-alone scorecard. Such context keeps CagriSema weight loss women research balanced.

5. Results were reported across menopause stages

The separate menopause-status analysis classified 1,902 women who had received CagriSema or placebo. Novo Nordisk reported estimated mean losses in the combination group of 26.7% before menopause, 24.8% during perimenopause and 23.1% after menopause, compared with placebo estimates of 2.1%, 1.7% and 2.6%, respectively. [1]

The pattern is encouraging as a research observation: reductions were reported in all three categories. But CagriSema weight loss women research does not establish that premenopausal participants respond biologically better than postmenopausal participants. The reported numerical ordering could reflect differences in baseline characteristics, uncertainty, chance, classification or other factors.

Critically, investigators did not prospectively collect validated reproductive-stage classifications or confirm stage biochemically. They derived categories afterward from age, recorded symptoms and medical history. This introduces potential misclassification, particularly around the transition years when experiences and hormone profiles vary. It is an important caveat for CagriSema weight loss women research.

6. Formal interaction testing was not performed

Novo Nordisk’s release explicitly states that formal treatment-by-sex interaction testing was not performed for the all-women analysis. For the menopause grouping, formal treatment-by-subgroup interaction testing was also not performed. Reported p-values were not adjusted for multiplicity. [1] These limitations are not minor footnotes; they define what can legitimately be concluded.

A within-group or treatment-versus-placebo comparison does not prove that the treatment effect differs between women and men. To support that conclusion, investigators would need an interaction analysis comparing treatment effects across sex categories, rather than simply observing that one subgroup has a notable mean.

Likewise, CagriSema weight loss women research cannot establish that menopausal stage modifies treatment efficacy without appropriately powered comparisons. Differences between subgroup point estimates can look persuasive while failing to survive uncertainty analysis. An honest interpretation recognizes promising signals and explicitly avoids declaring a proven sex-specific advantage. For CagriSema weight loss women research, the missing interaction tests are decisive.

7. The central question is what persists beyond the trial

REDEFINE 1 followed participants for 68 weeks, a meaningful period for a controlled efficacy study. It does not, by itself, answer every question about longer-term outcomes, treatment interruption, changes in body composition, or the durability of metabolic effects over several years. Durability is an open question in CagriSema weight loss women research.

The most useful contribution of CagriSema weight loss women research may therefore be a richer agenda for later trials. Investigators can now identify specific populations and endpoints to study prospectively, with robust reproductive staging, planned interactions and longer follow-up. The results help frame hypotheses; they do not close the scientific debate.

CagriSema weight loss women research: the numbers

The following table preserves the separation between the peer-reviewed primary study and the later company-reported exploratory analysis. This is essential because a 2025 journal result and an October 2026 conference-poster result differ in both population and statistical framing.

Evidence set	Population and analysis	Combination	Semaglutide alone	Cagrilintide alone	Placebo
REDEFINE 1 primary trial, NEJM 2025 [2]	3,417 randomized adults; week 68 treatment-policy estimand	−20.4%	Not tabulated here	Not tabulated here	−3.0%
REDEFINE 1 primary trial, NEJM 2025 [2]	Week 68 efficacy estimand	−22.7%	−16.1%	−11.8%	−2.3%
Women post-hoc, Novo-reported 2026 [1]	2,309 women; week 68 efficacy estimand	−25.0%	−19.0%	−13.4%	−3.0%

Important correction: The frequently repeated 22.7% figure from the overall REDEFINE 1 publication is the efficacy-estimand result, not the treatment-policy result. The 11.8% value belongs to cagrilintide alone, not semaglutide. The table labels both estimands so that figures are not inadvertently mixed. [2]

For the women-only four-arm analysis, the reported sample sizes by assignment were 1,441 combination, 199 semaglutide, 208 cagrilintide and 461 placebo. They sum to 2,309. The values reported in the company announcement are model-based efficacy estimates rather than unqualified observed changes for every enrolled woman. [1]

In CagriSema weight loss women research, even a seemingly small difference in labeling can materially change interpretation. A figure estimated under continued therapy answers a different question from one incorporating discontinuation or other real-world deviations. Both may be useful, but they cannot be swapped merely because they come from the same trial.

Menopause-stage estimates

Post-hoc category	CagriSema participants	Placebo participants	CagriSema estimated mean change	Placebo estimated mean change
Premenopausal	408	122	−26.7%	−2.1%
Perimenopausal	256	81	−24.8%	−1.7%
Postmenopausal	530	168	−23.1%	−2.6%

These values are from Novo Nordisk’s 2026 company report of poster P-50, using the efficacy estimand. The announcement also mentions a separate hormone-therapy category, so readers should not assume these three rows account for all 1,902 women. Classification was reconstructed after enrollment, and subgroup-interaction testing was not performed. [1] These are essential qualifications in CagriSema weight loss women research.

Why estimands and post-hoc design matter

An estimand defines the treatment effect a study seeks to estimate, including how it handles events such as participants stopping a study drug or starting another intervention. In obesity studies, this choice can affect the headline result. An efficacy estimand models a scenario of staying on assigned therapy without other weight-loss treatments, whereas a treatment-policy estimand reflects the randomized treatment strategy regardless of subsequent treatment deviations.

The question behind CagriSema weight loss women research is therefore not just “what percent?” but “under which analytical assumptions?” A percentage divorced from its estimand is easy to misunderstand. The 25.0% women-only estimate was reported under the hypothetical continued-treatment scenario. It should not be casually described as the average result that all women experienced in ordinary clinical practice.

Post-hoc analysis means researchers asked the specific question after the original study design was established. Such work is common and can be productive: a large trial creates information that can be reexamined by age, sex or other characteristics. Yet every extra comparison introduces opportunities for selective findings, confounding and multiple-testing problems. That is the methodological backdrop of CagriSema weight loss women research.

In this instance, the treatment assignment in the original trial was randomized. Membership in a menopausal category, however, was not randomized. It was inferred afterward using available records. Randomization protects many comparisons between original treatment groups, but it does not automatically make every newly defined subgroup exchangeable or power an interaction analysis.

For readers evaluating CagriSema weight loss women research, the hierarchy of evidence is important. The peer-reviewed primary trial supports the main comparison under its prespecified analysis. The 2026 conference findings supply secondary, exploratory descriptions in women. Neither automatically proves that the combination is better for women than men or that age-related hormonal changes explain the numerical pattern.

Consider how an apparent subgroup difference might arise. If one category had different baseline weights, discontinuation patterns, comorbidities or missing-data characteristics, estimated outcomes could shift. Statistical models can address measured variables to a degree, but an unplanned analysis cannot eliminate all uncertainty. Careful replication is the way to distinguish a reproducible biological pattern from a chance observation. Replication should follow CagriSema weight loss women research.

There is also a publication-status issue. The company’s press release references poster presentations and provides selected analyses; it is not identical to independent peer review of the full subgroup dataset. CagriSema weight loss women research is newsworthy because the results are specific and source-attributed, but the reporting format should remain visible to anyone relying on it.

Menopause, hormones and scientific uncertainty

Menopause is not a single instant with identical physiological effects for every woman. Reproductive aging involves changing ovarian hormone patterns, shifts in symptoms and differences in body-fat distribution. Midlife weight trends can also involve sleep, activity, medications, stress and social context. Separating these influences requires purpose-built research rather than relying on age alone.

The menopausal staging used in the company-reported analysis was reconstructed from age ranges, clinical history and symptoms, without prospectively measured hormones or a standardized staging assessment. This is a practical way to explore existing data, but it is a less precise instrument than a study designed from the outset to collect reproductive status in a consistent manner. [1]

An open question within CagriSema weight loss women research is whether absolute body-weight change, percentage change and changes in fat distribution tell the same story at each reproductive stage. Percentages normalize some differences in starting body mass, but they do not fully account for variations in lean tissue, central adiposity or metabolic health.

Another unanswered question concerns hormone therapy. Novo Nordisk says investigators analyzed women receiving hormone therapy separately, irrespective of age, menopausal status or indication. The press release does not provide enough detail to conclude that hormone therapy caused a stronger or weaker CagriSema response. Observational associations within such a category would need particularly careful control of confounding. CagriSema weight loss women research leaves this issue unresolved.

It is tempting to treat the pre-, peri- and postmenopausal point estimates as a biological ranking. That would overreach. CagriSema weight loss women research is better read as evidence that meaningful estimated reductions were observed across these retrospectively defined groups, with uncertainty about whether their apparent differences reflect true effect modification.

Researchers could improve this area with prespecified reproductive-stage definitions, repeated hormone and symptom assessments, explicit reporting of hormone-therapy exposure, and sufficiently powered interaction tests. Imaging-based measures of fat distribution and functional outcomes would help connect anthropometric change to physiology. These are proposals for research design, not claims that the existing trial already answered those questions.

Safety signals and study boundaries

The published REDEFINE 1 study and Novo Nordisk’s summary describe a substantial burden of gastrointestinal adverse events. The company’s October 2026 release reports that 79.6% in the CagriSema group experienced gastrointestinal events versus 39.9% with placebo; it lists nausea at 55.0% versus 12.6%, constipation at 30.7% versus 11.6%, and vomiting at 26.1% versus 4.1%. [1,2]

The same source reports discontinuation because of adverse events in 5.9% of CagriSema participants and 3.5% of placebo participants in the main trial. These are full-trial figures, not separately established safety rates for each menopause subgroup. The distinction matters because subgroup efficacy results should not be paired with an invented subgroup-specific safety profile.

Safety is inseparable from interpreting CagriSema weight loss women research. Weight-change averages do not show tolerability for a particular person, and a trial’s eligibility criteria, monitoring and follow-up may not mirror a broader population. Other adverse events and longer-term risks require evaluation in the complete study documentation and subsequent evidence.

As of the October 20, 2026 company announcement, CagriSema remained investigational and was not approved in the United States. Novo Nordisk said it submitted a U.S. new drug application in December 2025 and expected an FDA decision in the fourth quarter of 2026. An expected decision is not an approval. This article does not assume any Canadian market authorization or represent an investigational product as an available consumer therapy. [1]

The study enrolled adults without type 2 diabetes. Results cannot simply be transferred to all people living with diabetes, to adolescents, to those excluded under the protocol, or to individuals with substantially different health profiles. Separate research programs may address different populations, but those findings should not be silently merged with REDEFINE 1. Population boundaries matter in CagriSema weight loss women research.

Ultimately, CagriSema weight loss women research needs to be discussed with both its efficacy signal and its safety and regulatory boundaries in view. Strong average outcomes are an important scientific observation, not a substitute for regulatory review or individualized clinical decisions.

What researchers should investigate next

First, a prospective trial or prespecified pooled analysis could test whether sex genuinely modifies the combination’s effect. That requires an interaction estimate with an uncertainty interval, sufficient statistical power and a transparent multiplicity strategy. A comparison showing that women have a large within-group reduction is not itself that test.

Second, reproductive-stage analysis should be built into the protocol instead of reconstructed afterward. Standardized definitions would reduce classification ambiguity. The finding in CagriSema weight loss women research that different menopause groups all showed estimated weight reductions is a rational reason to investigate further, not proof of a stage-specific mechanism.

Third, future work could distinguish total weight loss from changes in lean mass, fat mass, visceral adiposity, muscle strength and physical function. Those measures would be especially valuable across aging-related transitions. A waist-circumference change is useful, but it cannot replace direct body-composition measurements.

Fourth, follow-up should address durability and discontinuation. What happens after the 68-week observation period? How do interruptions, adherence changes and supportive care influence estimated outcomes? A clearer account would help bridge the gap between an idealized efficacy estimand and a treatment-policy or real-world question.

Fifth, subgroup-specific safety reports would add context. CagriSema weight loss women research has precise efficacy figures for several retrospective groups, but readers should not assume that tolerability is uniform across reproductive stages. Reporting complete adverse-event categories, discontinuation, exposure and uncertainty would strengthen the evidence base.

Sixth, independent peer-reviewed publication of the exploratory analyses would allow a closer evaluation of statistical methods, missing-data handling and full outcome reporting. Conference posters and company summaries can communicate early results quickly. Detailed publication helps the scientific community scrutinize and reproduce interpretation. That would strengthen CagriSema weight loss women research.

Finally, all future comparisons should retain the same disciplined language: an association reported in a post-hoc analysis is not equivalent to proof of a differential causal effect. The enduring contribution of CagriSema weight loss women research is a testable set of questions about obesity biology, reproductive aging, effectiveness and tolerability.

Frequently asked questions

1. What did the REDEFINE 1 women’s post-hoc analysis report?

According to Novo Nordisk’s October 20, 2026 announcement, 2,309 women were included in a post-hoc analysis, with estimated mean weight loss of 25.0% for CagriSema versus 3.0% for placebo at week 68 under the efficacy estimand. CagriSema weight loss women research reports a company-presented exploratory finding, not a new women-only randomized trial. [1]

2. Was the women’s analysis presented at EASD 2025?

No. The women-focused post-hoc results described here were presented at The Menopause Society 2026 Annual Meeting in San Diego, in posters P-51 and P-50. The underlying REDEFINE 1 primary trial was published in the New England Journal of Medicine in 2025. These are distinct events and evidence formats. [1,2]

3. Did the study prove CagriSema works better in women than men?

No. Novo Nordisk states that formal treatment-by-sex interaction testing was not performed in the women-only post-hoc analysis. CagriSema weight loss women research therefore cannot establish a statistically demonstrated treatment advantage specific to women, even though the reported women’s average was substantial. [1]

4. Were weight changes reported before, during and after menopause?

Yes. In a separate post-hoc analysis, the company reported estimated mean combination-group changes of −26.7%, −24.8% and −23.1% across retrospectively defined premenopausal, perimenopausal and postmenopausal categories. Formal treatment-by-subgroup interaction tests were not conducted, so these numerical differences should not be interpreted as proven stage effects. [1]

5. Is CagriSema approved based on these findings?

No. In its October 20, 2026 announcement, Novo Nordisk identified CagriSema as investigational and not approved in the United States, with an FDA decision expected in the fourth quarter of 2026. An application or anticipated decision is not authorization. CagriSema weight loss women research is educational reporting about trial evidence, not product availability or consumer use. [1]

References

1. Novo Nordisk. Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting. Company announcement, October 20, 2026. Reports posters P-51 and P-50 by Hurtado Andrade MD and colleagues. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=918569
2. Garvey WT, Blüher M, Osorto Contreras CK, et al.; REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393:635–647. doi:10.1056/NEJMoa2502081. https://pubmed.ncbi.nlm.nih.gov/40544433/

For laboratory research use only. Not for human consumption.